References
- Narayan R, Simpson A, Fritsche K, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. J Mult Scler Relat Disord. 2018;25:66–72.
- Wang L, ZhangBao J, Zhou L, et al. Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China. Eur J Neurol. 2019;26(1):168–174.
- Salama S, Khan M, Levy M, et al. Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. J Mult Scler Relat Disord. 2019;29:15–22.
- Zhou L, Huang Y, Li H, et al. MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients. J. Neuroimmunol. 2017;305:19–28.
- Fujimori J, Takai Y, Nakashima I, et al. Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. J Neurol Neurosurg Psychiatry. 2017;88(6):534–536.
- Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4(2):e322.
- Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. J Brain. 2017;140(12):3128–3138.
- Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relaping MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127–137.